Previous Article | Next Article ![]()
Journal of Clinical Microbiology, October 2000, p. 3561-3571, Vol. 38, No. 10
Laboratory of Human Bacterial Pathogenesis, Rocky Mountain
Laboratories, National Institute of Allergy and Infectious Diseases,
National Institutes of Health, Hamilton, Montana
59840,1 and Division of Vector-Borne
Infectious Diseases, National Center for Infectious Diseases,
Centers for Disease Control and Prevention, Fort Collins, Colorado
805222
Received 20 March 2000/Returned for modification 2 June
2000/Accepted 28 July 2000
Human louse-borne relapsing fever occurs in sporadic outbreaks in
central and eastern Africa that are characterized by significant morbidity and mortality. Isolates of the causative agent,
Borrelia recurrentis, were obtained from the blood of four
patients during a recent epidemic of the disease in southern Sudan. The
glpQ gene, encoding glycerophosphodiester
phosphodiesterase, from these isolates was sequenced and compared with
the glpQ sequences obtained from other relapsing-fever
spirochetes. Previously we showed that GlpQ of Borrelia
hermsii is an immunogenic protein with utility as a serological
test antigen for discriminating tick-borne relapsing fever from Lyme
disease. In the present work, we cloned and expressed the
glpQ gene from B. recurrentis and used
recombinant GlpQ in serological tests. Acute- and convalescent-phase
serum samples obtained from 42 patients with louse-borne relapsing
fever were tested with an indirect immunofluorescence assay (IFA) and
an enzyme-linked immunosorbent assay (ELISA) that used whole cells of
B. recurrentis and with immunoblotting to whole-cell
lysates of the spirochete and Escherichia coli producing
recombinant GlpQ. The geometric mean titers of the acute- and
convalescent-phase serum samples measured by IFA were 1:83 and 1:575,
respectively. The immunoblot analysis identified a high level of
reactivity and seroconversion to GlpQ, and the assay was more sensitive
than the whole-cell IFA and ELISA using purified, recombinant
histidine-tagged GlpQ. Serum antibodies to GlpQ and other antigens
persisted for 27 years in one patient. We conclude that assessment of
anti-GlpQ antibodies will allow serological confirmation of louse-borne relapsing fever and determination of disease prevalence.
0095-1137/00/$04.00+0
Serodiagnosis of Louse-Borne Relapsing Fever with
Glycerophosphodiester Phosphodiesterase (GlpQ) from
Borrelia recurrentis
*
Corresponding author. Mailing address: Rocky Mountain
Laboratories, 903 S. Fourth St., Hamilton, MT 59840. Phone: (406)
363-9250. Fax: (406) 363-9445. E-mail:
tom_schwan{at}nih.gov.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»